Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Boosted by NBC Securities Inc.

NBC Securities Inc. grew its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 748.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,725 shares of the biotechnology company’s stock after purchasing an additional 2,404 shares during the period. NBC Securities Inc.’s holdings in Blueprint Medicines were worth $252,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Creative Planning lifted its stake in Blueprint Medicines by 6.8% in the 3rd quarter. Creative Planning now owns 13,194 shares of the biotechnology company’s stock worth $1,220,000 after acquiring an additional 843 shares in the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of Blueprint Medicines in the 3rd quarter valued at about $3,280,000. Clarus Wealth Advisors lifted its position in shares of Blueprint Medicines by 8.6% in the third quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 206 shares in the last quarter. CWM LLC boosted its holdings in shares of Blueprint Medicines by 69.2% during the third quarter. CWM LLC now owns 1,870 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 765 shares during the period. Finally, Clearbridge Investments LLC purchased a new position in Blueprint Medicines during the second quarter valued at approximately $23,817,000.

Blueprint Medicines Stock Performance

Blueprint Medicines stock opened at $86.00 on Friday. Blueprint Medicines Co. has a 52 week low of $43.89 and a 52 week high of $121.90. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.65 and a current ratio of 3.71. The firm has a market capitalization of $5.39 billion, a PE ratio of -17.88 and a beta of 0.58. The business’s 50-day simple moving average is $90.49 and its 200-day simple moving average is $98.73.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.49. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The firm had revenue of $138.20 million for the quarter, compared to analyst estimates of $104.02 million. During the same quarter last year, the firm posted ($2.19) EPS. The company’s revenue was up 139.9% on a year-over-year basis. Equities research analysts forecast that Blueprint Medicines Co. will post -3.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Oppenheimer increased their target price on shares of Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, July 8th. Baird R W raised Blueprint Medicines to a “strong-buy” rating in a research report on Friday, August 2nd. Robert W. Baird boosted their target price on Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Guggenheim raised their price target on Blueprint Medicines from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $130.00 price target on shares of Blueprint Medicines in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Blueprint Medicines has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

Insider Buying and Selling

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of the stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now directly owns 69,070 shares of the company’s stock, valued at $6,169,332.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Philina Lee sold 41,913 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the transaction, the insider now directly owns 34,729 shares in the company, valued at $3,236,395.51. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Fouad Namouni sold 3,633 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares of the company’s stock, valued at $6,169,332.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.